Medicinal chemistry in the development and implementation of selective targeted drugs in clinical practice
Transcript of scientific report at the meeting of the Presidium of NAS of Ukraine, September 18, 2024
DOI:
https://doi.org/10.15407/visn2024.11.056Abstract
The report presents some of the most important results of current research by scientists of the O.V. Bogatsky Physico-Chemical Institute of the National Academy of Sciences of Ukraine on the development of targeted drugs. The proposed approaches and the obtained results are promising for the targeted search and development of new effective drugs, in particular, using the concept of polymodality of pharmacological effect realization through receptor-oriented and receptor-selective mechanisms.
References
Golovenko M.Ya., Larionov V.B., Reder A.S., Andronati A.S. The discovery and development of propoxazepam, a novel analgesic and anticonvulsant with multimodal mechanism of action: review of own preclinical data. EAS Journal of Pharmacy and Pharmacology. 2020. 2(3): 83—87. https://doi.org/10.36349/easjpp.2020.v02i03.13
Golovenko M.Ya., Larionov V.B., Reder A.S., Valivodz' I.P., Yurpalova T.O. Pharmacodynamics of interaction between propoxazepam and GABA-benzodiazepine receptor-ionophore complex. Neurophysiology. 2018. 50(1): 2—10. https://doi.org/10.1007/s11062-018-9711-9
Reder A., Larionov V., Golovenko M. Subunit-dependent interaction of propoxazepam and its metabolite with the γ-aminobuturic acid type A receptor. EUREKA: Health Sciences. 2022. (5): 10—18. https://doi.org/10.21303/2504-5679.2022.002649
Golovenko M.Y., Larionov V.B., Reder A.S., Valivodz I.P., Mykhailova T.V. Antagonism of GABAA-receptor complex allosteric modulators – propoxazepam and bemegride, possessing affinity to different macromolecule subunits. Medical and Clinical Chemistry. 2018. 20(2): 18—26. https://doi.org/10.11603/mcch.2410-681X.2018.v0.i2.8638
Golovenko M.Ya., Shtrygol' S.Yu., Larionov V.B., Lytkin D.V., Valivodz' I.P., Reder A.S. Evaluation of the alpha isoforms of the GABA receptor in the implementation of the pharmacological action of propoxazepam. Pharmacology and Drug Toxicology. 2023. 17(3): 177—188. https://doi.org/10.33250/17.03.177
Golovenko N.Ya., Voloshchuk N.I., Andronati S.A., Taran I.V., Reder A.S., Pashynska O.S., Larionov V.B. Antinociception induced by a novel benzodiazepine receptor agonist and bradykinin receptor antagonist in rodent acute and chronic pain models. European Journal of Biomedical and Biopharmaceutical Sciences. 2018. 5(12): 79—88.
Golovenko N.Ya., Kabanova T.A., Andronati S.A., Halimova O.I., Larionov V.B., Reder A.S. Anti-inflammatory effects of propoxazepam on different models of inflammation. International Journal of Medicine and Medical Research. 2019. 5(2): 105—112. https://doi.org/10.11603/ijmmr.2413-6077.2019.2.10900
Golovenko M.Y., Babenko M.M., Larionov V.B., Zhukova N.O., Tkachenko E.V., Valivodz' I.P. In vitro study of drug interaction mediated by cytochrome P450 isozymes. Methodological recommendations. Ministry of Health of Ukraine. State Expert Center. Kyiv, 2023 [in Ukrainian].
Golovenko M., Reder A., Zupanets I., Bezugla N., Larionov V., Valivodz' I. A phase I study evaluating the pharmacokinetic profile of a novel oral analgesic propoxazepam. J. Pre Clin. Clin. Res. 2023. 17(3): 138—144. https://doi.org/10.26444/jpccr/169426
Golovenko M.Ya., Kuz’min V.E., Artemenko A.G., Larionov V.B., Ognichenko L.M., Kichova M.E., Valivodz I.P. Determination of the pharmacokinetic drug interaction of propoxazepam using an in silico model. Pharmacology and Drug Toxicology. 2024. 18(2): 107—114. https://doi.org/10.33250/18.02.107
Golovenko M.Y., Larionov V.B., Valivodz I.P. Spectral characteristics of cytochrome P450 in the interaction with propoxazepam and its metabolite. Medical and Clinical Chemistry. 2023. 25(2): 12—19. https://doi.org/10.11603/mcch.2410-681X.2023.i2.13854
Larionov V., Golovenko M., Kyz’min V., Valivodz’ I., Nefedov O. Propoxazepam interaction with cytochromes P450 isoforms based on molecular docking analysis. Dopov. Nac. Akad. Nauk Ukr. 2023. (3): 96—104. https://doi.org/10.15407/dopovidi2023.03.096
Golovenko M.Y., Larionov V.B., Valivodz I.P. Correction with flumazenil of the pharmacological effects of benzodiazepine derivatives diazepam and propoxazepam. In: Medicine and psychology: modern problems, new technologies and ways of developing outdated theories. International Science Group. Boston: Primedia eLaunch, 2024. https://doi.org/10.46299/ISG.2024.MONO.MED.1.12.2
Orlenko O.B., Voloshyuk N.I., Basok S.S., Larionov V.B., Golovenko M.Ya. Gabalgin pharmacokinetics in mice. Pharmacology and Drug Toxicology. 2023. 17(2): 108—114. https://doi.org/10.33250/17.02.108
Larionov V.B., Nefodov O.O., Kalbus O.I., Titov G.I., Nefodova O.O., Onul N.M., Rutgaizer V.G. Computer simulation of the combined use of azathioprine with methylprednisolone under the conditions of pharmacotherapy of myasthenia gravis. World of Medicine and Biology. 2022. (3): 88—93. https://doi.org/10.26724/2079-8334-2022-3-81-88-93
Larionov V.B., Golovenko M.Y., Akisheva A.S., Valivodz I.P., Borysiuk I.Y., Molodan Y.O., Makarenko O.A. Molecular insights into propoxazepam interaction with trpv1 receptors: a docking analysis. Odesa National University Herald. Biology. 2023. 28(2): 99—112. https://doi.org/10.18524/2077-1746.2023.2(53).293324
